Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691909 | PMC |
| http://dx.doi.org/10.1016/j.xjtc.2021.11.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The interface in home non-invasive ventilation: is the nasal mask better?
Eur Respir J
January 2025
Sleep Disorders Clinic, Division of Pulmonary Medicine, Villa Sofia-Cervello Hospital, Palermo, Italy
Disarming the cavalry: targeting neutrophils to limit collateral damage in non-CF bronchiectasis.
Eur Respir J
January 2025
Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
Eur Respir J
January 2025
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Reply to: Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
Eur Respir J
January 2025
Center for Congenital Heart Diseases, Paediatric and Congenital Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Overlap Syndrome (COPD and OSA): A Treatable Trait for Triple Treatment?
Pulm Ther
January 2025
MSc Program in Sleep Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient is referred to as overlap syndrome (OS). Patients with OS suffer more frequently from cardiovascular disease (CVD) and carry a higher risk of COPD-related exacerbations than patients with COPD alone, especially when OSA is left untreated. Based on recent evidence, triple therapy, namely inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-agonist (ICS-LABA-LAMA), is a treatment strategy in COPD patients with a history of exacerbations and/or CVD comorbidity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!